LPL Financial’s Regenxbio RGNX Stock Holding History

LPL Financial’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$120K	Buy	+10,000	New	+$83K	﹤0.01%	5887

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LPL Financial's RGNX Position: Q1 2026 in Review

LPL Financial sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 32,705 shares — an estimated $471K sold.

LPL Financial first reported a position in RGNX in Q1 2019 and held it in 7 quarters. The position peaked at $471K in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

LPL Financial reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
LPL Financial sold 32,705 Regenxbio shares in Q1 2026, an estimated $471K.
LPL Financial first reported a position in Regenxbio in Q1 2019 and held it in 7 quarters.
LPL Financial's Regenxbio position peaked at $471K in Q4 2025.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.